Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2- negative early breast cancer and Oncotype DX Recurrence Score ‡18: DxCARTES study

The effect of the addition of cyclin-dependent kinases 4 and 6 inhibitors to endocrine therapy in terms of molecular downstaging remains undetermined. Switching from a high-risk to a low risk Recurrence Score (RS) group could provide useful information to identify patients who might not require chem...

ver descrição completa

Detalhes bibliográficos
Autores: Guerrero-Zotano, Á., Pérez-García, J. M., Ruiz-Borrego, M., Bermejo, B., Gil-Gil, M., de la Haba, J., Alba Conejo, E., Quiroga, V., Carañana, V., Urruticoechea, A., Morales, S., Bellet, M., Antón, A., Fernández-Abad, M., Sánchez-Rovira, P., Calabuig, L., Pérez-Escuredo, J., Sampayo-Cordero, M., Cortés, J., Llombart Cussac, Antonio
Formato: artículo
Fecha de publicación:2024
País:España
Recursos:Universidad Católica de Valencia San Vicente Mártir
Repositorio:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
Idioma:inglés
OAI Identifier:oai:riucv.ucv.es:20.500.12466/4801
Acesso em linha:http://hdl.handle.net/20.500.12466/4801
Access Level:acceso abierto
Palavra-chave:Palbociclib
Letrozole
Hormone-receptor-positive
Early breast cancer
Oncotype
32 Ciencias Médicas
Descrição
Resumo:The effect of the addition of cyclin-dependent kinases 4 and 6 inhibitors to endocrine therapy in terms of molecular downstaging remains undetermined. Switching from a high-risk to a low risk Recurrence Score (RS) group could provide useful information to identify patients who might not require chemotherapy. The purpose of this study was to assess the biological and clinical activity of letrozole plus palbociclib as neoadjuvant treatment for patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with an initial Oncotype DX RS !18.

Registos relacionados